INTRODUCTION
The Global Program on AIDS of the World Health Organization (WHO) estimates that more than one million cases of AIDS had occurred worldwide by 1992 and another 10 to 12 million adults were infected with HIVI. With the rise of the AIDS epidemic, the last decade has also seen a marked worldwide increase in the number of people injecting drugs for non-medicinal purposes-. Up to five million of these drug injectors may be routinely sharing injection equipment-', a critical factor in the global spread of HIV infection.
In some regions of the world drug injection is a predominant mode of HIV transmission. In Australasia and Southeast Asia, especially in Thailand, drug injection was a major contributor to the initial spread of the HIV epidemic'. In Southern Europe, Italy and Spain report that about 65% of their cumulative AIDS cases are attributed to drug injections, while the United States of America reports that 23% of 214609 cumulative adult AIDS cases are attributed to this mode of transmissions. In other regions of the world, such as Latin America, the important role and effect of drug injection on the evolution of the AIDS epidemic is barely beginning to be recognized.
It is estimated that one million HIV infected people live in Latin America and the Caribbean", and that by the end of 1995there will be two million (PAHO internal report). Although there are no estimates of the number of drug injectors in Latin America and the Caribbean, anecdotal evidence indicates that their number is increasing as well.
The increase in HIV infection in Latin America and the Caribbean is primarily attributable to heterosexual transmission of the virus. However, in some areas of Latin America and the Caribbean the increase in HIV infection is also attributable to drug injection. By the end of 1992, 13% of the 63849 cumulative AIDS cases reported in Latin America and the Caribbean were attributed to drug injection (PAHO internal report); however, this proportion varies widely from one subregion to another.. For instance, in the Andean Area, the Central Amencan Isthmus, Mexico and the Caribbean Basin, the proportion of AIDS cases resulting from drug injection is 1.6% or less. In contrast, in the Southern Cone (Argentina, Chile, Paraguay, and Uruguay) and Brazil, the proportion of all AIDS cases attributed to drug injection has reached 22%. Among these countries, Argentina has the highest proportion of cases resulting from drug injection (27%), making it a leading risk factor among AIDS cases", Argentina has reported a total of 1820 cumulative AIDS cases through 1992. Since the first AIDS case in a drug injector was reported in 1987, the proportion of cases attnbuted to drug injection has steadily increased, rising from 11.3% in 1987 to 39% in 1991. Similarly, the proportion of AIDS cases attributed to drug injection in Brazil increased from 1.8% in 1985to over 30% of the 3935cases with known transmission category reported in 1991 (PAHO internal report). By September 1992,31364 cumulative AIDS cases had been reported in Brazil ( Figure 1 ).
The data presented highlight the importance of drug injection in HIV transmission in Argentina and Brazil. However, this information is limited by the nature of the data obtained from epidemiological surveillance sources of reported AIDS cases. To complement this information, this paper reviews available epidemiological information to assess the level, trends and risk factors of HIV infection among drug injectors in Brazil and Argentina.
HIV INFECTION AMONG DRUG INJECTORS OF BRAZIL AND ARGENTINA

Sources of information on HIV infection among drug injectors
Searches were performed in international (AIDSline) and local bibliographic data bases to identify available publications on the issues of prevalence, incidence, co-infection patterns, and risk factors of HIV infection among drug injectors in Argentina and Brazil. In addition, personal communications were sought from researchers of on-going studies addressing these issues. In all, 42 publications and personal communications were collected, 24 from Argentina and 18 from Brazil.
Sample sizes of these studies varied from 9 to 1631 drug injectors; median sample size was 68 in Brazil and 188 in Argentina. Most of the studies selected their samples from outpatient facilities, with only 5 studies conducted among inpatients and 14 carried out among patients of drug rehabilitation centres, In half of the studies reviewed, males constituted more than two-thirds of the sample, perhaps indicating that drug injection is less frequent among women than men, although selection bias cannot be totally disregarded. Measures of central tendency of age, as reported in each study, varied between 16 and 29 years of age among all but one of the 19 studies reporting mean or median age.
Temporal trends of HIV infection among drug injectors
Information on HIV prevalence was classified by the year in which the results were obtained to explore temporal trends of HIV infection. However, studies providing only one figure for HIV prevalence for a period of more than one year were not considered in the trend analysis. Pearson's correlation Was then calculated between HIV prevalence and year of result by country, only for those studies that sampled more than 40 individuals. 70 60 and year of study was 0.82 (P=O.01). Studies from Argentina also show an increase of HIV seroprevalence in time 14 -16 , however, the rate of increase was not as pronounced as in Brazil. Pearson's correlation between HIV seroprevalence and year of the study for Argentina was 0.53 (P=0.03). Some care should be taken when interpreting these trends. First, all studies reviewed here are based on convenience rather than on probability samples. More specifically, individuals selected for the samples were seeking some kind of care at the centres from which the samples were drawn. Second, the trends were calculated using data from studies that may represent very different populations. However, the upward trend shown in the correlational analysis seems to be confirmed by 2 large studies that reported 4 consecutive yearly prevalence rates for the same populations. One study performed in Buenos Aires among 1507 drug injectors in treatment at 2 drug rehabilitation centres showed that seropositivity increased from 29% in 1987 to 47.4% in 1990 for one of the centres (X 2 linear trend P<0.OO1), and from 38% in 1987 to 46% in 1990 for the other (X2 linear trend P=O.31) (Libonatti, unpublished data). Furthermore, among 1508 drug injectors screened for HIV in the city of Rosario, seropositivity rose from 28% in 1988 to 39 .7% in 1990 (X2 linear trend P<O.001)17.
Some authors have suggested that the rapid spread of HIV among drug injectors has been facilitated by the lack of awareness of the local AIDS threat and the presence of a mechanism for' efficient mixing' of the HIV infected and uninfected populations". In addition, the type of drug injected may contribute to the rapid increase of HIV infection among drug injectors. Contrary to most HIV pattern I countries, cocaine rather than heroin is the injected drug of choice in Argentina and Brazil. Several investigators have reported that injectors of stimulant drugs, such as cocaine, are more likely to be HIV infected than are heroin injectorsl". The practice of 'booting', in which blood is drawn into the syringe and then injected-", and the need to inject more frequently to maintain the effects of cocaine, may account for this increased risk. Figures 2 and 3 present the evolution of HIV seroprevalence among drug injectors in Argentina and Brazil based on data from selected studies. In both countries HIV seroprevalence among drug injectors has increased rapidly. In Brazil, HIV seroprevalence, although detected earlier and at a lower level than in Argentina, seems to be increasing at a faster pace. For example, HIV prevalence in Brazil rose from 4.4% in 1986 7 to between 38% and 57%8-11, in 1991 depending on the study, with a peak of 74% in 1988 12 ,13. The 1988 study was excluded from correlation analysis, however, because it was considered an outlier. Pearson's correlation between HIV seroprevalence
Level of HIV infection in different subpopulations of drug injectors
HIV seroprevalence among drug injectors varies according to the origin of the sample recruited. In particular, several studies reported HIV seroprevalence for samples recruited among STD clinic attenders, incarcerated persons, prostitutes, and street children.
STD clinic attenders
Two studies in Argentina reported HIV seroprevalence among SrD clinic attenders. In one of these studies, 11% of the 339 male and female heterosexual attenders of the STD clinic of the university hospital of Buenos Aires were drug injectors, and of this group, almost two-thirds 65.8%) were HIV infected'>. Another study done m north Greater Buenos Aires, reported 51.9% seropositivity among 541 drug injectors consulting for venereal diseases (Noguero, unpublished data).
Incarcerated persons
A study of 1631 drug injectors from various institutionalized groups found that HIV seropositivity ranged from 35% in adult prisoners 15 to 60.9% in incarcerated adolescents-'. Another study conducted in Buenos Aires pointed out that 45% of adolescents lodged in security institutes were drug injectors and presented higher HIV seropositivity (53.5%) than non-drug injectors (2.3%)22. In Sao Paulo State's prisons, 18% of 284 female inmates who volunteered to be tested~r e. found to be HIV positive in 1987. Drug nject~on was the most important risk factor for HIV infection for 90.4% of these HIV positive female inmates-'.
Prostitutes
Two studies reported HIV infection prevalence data among female drug injector prostitutes in the city of Buenos Aires. One stud y24 indicated an HIV seroprevalence of 20% for drug injector prostitutes in 1988. The other, conducted among the same prostitute population during 1989 and 1990, found a seroprevalence of 50% for drug injector prostitutes and 11% for all prostitutes of the same sample". Seroprevalence among female prostitutes varied from 2% in 1987 in northeast Argentina-" to 11.8% in 1991 in Buenos Aires 25 , and from 6.5% in 1988 in Ri0 27 to 27.7% in 1989 in Sorocaba (Brazil)28. The proportion of drug injectors in these samples ranged from 4.5% to about 10%. One study reported a 33% HIV seroprevalence among male prostitutes in Buenos Aires 23 • The proportion of drug injectors among them, however, was not indicated. Another study reported a 62% HIV seroprevalence among Brazilian transvestites, half of whom were drug injectors-".
Street children
One study performed during 1987-1988among 3389 street children (homeless, orphan, or juvenile offenders) in Rio de Janeiro, who were referred to FUNABEM Hospital in Rio, displayed a sero-pr~valence of 13.2% for HIV among 68 drug injector mmors between 10 and 18 years of age 30 . In Belo Horizonte 2 studies were conducted among street children admitted to social care institutions 31 and a juvenile detention centre 32. In the first study only one out of 529 children was found to be positive for HIV. In the second, 4 out of 414 children and adolescents (1.2%) were HIV positive; however, only 4% of these young people acknowledged drug injecting behaviour.~a~t ors associated to HIV infection among drug Injectors HIV infection among drug injectors has been related to the injector's sociodemographic factors and their injecting and sex practices. In a sample of 213women attending an HIV clinic in the city of Buenos Aires O~/o were HIV positiv~and of these, 89%were drug mJ~ctors33. Four studies cited HIV seroprevalence estimates by gendera,34-36. In 3 of these studies, HIV gend~r differences were not statistically significant, a~d.~n the. other, men had only a marginally SIgnificant higher seroprevalence (Fisher's exact 2-tail P=0.05). One study in Buenos Aires revealed that 66.2% of drug injectors of low socioeconomic status wer~infected, compared to 36.6% of drug injectors of hIf?her socioeconomic status, with both groups recrwte? from the same STD clinic (Noguero B, et al, unpublished data, 1992) . No age differences were reported in HIV seroprevalence.
Few studies have explored risk factors for HIV infection among drug injectors in Argentina and r.azil. S~ver~l recent studies report that drug njectors m RIO de Janeiro are more likely to be mfected if they inject 4 or more times a week (P< 0.01) or have been injecting drugs for more than 5 years (OR=3.4; CI 1.2-11.3)37. However, no other s~dy :eported frequency of injection and onlỹ .stU?IeS CIted mean length of history of drug n~ect~on. I~these studies mean duration of drug injection history was 3.4 years in Argentina 38 and 11.6 years in Brazil-", A comparison between the behaviour of Rio de Janeiro's drug injectors and that of drug injectors in New York City (USA) indicates hat~ewer Brazilian injectors share equipment (31% m RIO vs. 46% in New York City; P<0.01); but am~ng those in Brazil who share, fewer clean the equipment (81% in Rio vs. 97% in New York City' P<O.Ol)40. Moreover, of those who clean the' equipment, more Brazilians merely use cold water (82% in Rio vs. 31% in New York City; P<O.OI).
A logistic regression analysis performed on data from a study in Rio de Janeiro using the methodology of a WHO multicity study4l, identified ?r!gi~and forms of ris~behaviour other than drug injection that serve as risk factors for HIV infectioñ~o ng drug injec~~rs compared to non-drug injectors. More specifically, recruitment of samples from treatment centres (OR=3.03; CI 1.0-9.2) and homosexual/bisexual behaviour (OR=2.76; CI 1.02-7.4) were shown to be major risk factors for HIV infection among drug injectors-".
HIV co-infection patterns among drug injectors
Some studies reported co-infection patterns among drug injectors. Concomitant HIV-l and HTLV-I serop~si.tivity was f?und in 20%.of 85 HIV positive drug injectors, while HTLV-I Infection was not found in HIV negative drug injectorsv. Among se~onegative drug injectors, however, there was evidence of retroviral latent HIV-1 and HTLV-I infections. Polymerase chain reaction detected HIV-1 retroviral sequences in 21 .5% of the seronegative drug injectors and HTLV-I sequences in 14% of them. Only one serone~ative drug injector had sequences of both viruses .
The prevalence of syphilis, toxoplasmosis, and Chagas' disease was found not to be significantly different among HIV positive and negative drug injectors, according to a study of 212 individuals in Buenos Aires 44 • In Brazil, 4.4% of 68 drug injector minors between 10 and 18 years of age were infected with Treponema pallidunr".
The prevalence of hepatitis B virus (HBV) markers was found to be around 60% in HIV positive drug injectors in 6 different studies conducted in Buenos Aires and Rosari0 22 • 44 -48 • Hepatitis delta virus (HDV) prevalence was found to be 3 times higher among HBV+ HIV + drug injectors than among HBV+ HIV + non-drug injectors'", However, HDV prevalence was found to be similar among HIV positive and negative drug injectors.
CONCLUSIONS
Surveillance data show that drug injectors represent a rapidly growing proportion of AIDS cases in Argentina and Brazil. Drug injection has become the second largest HIV transmission category in both countries, as is the case in many pattern I countries'f.
HIV seroprevalence among drug injectors is increasing rapidly. These data suggest that the expanding proportion of AIDS cases due to drug injection stems from an absolute increase in the number of AIDS cases among drug injectors, and is not merely reflective of a decline in the proportion of cases reported in other transmission categories.
HIV infection among drug injectors poses a threat to their sex partners and offspring, becoming a bridge through which HIV reaches the heterosexual population, especially women. Recent increases in AIDS cases among women are related to heterosexual transmission and drug injection'" (Ministerio da Saude, Brazil, 1992). The increase in HIV infection among women may have a devastating effect on their offspring. Surveillance data show that perinatal cases in Latin America have increased from 45% of all paediatric AIDS cases in 1989 to 82% in 1991. Furthermore, one study conducted in Argentina and Brazil showed that 69% of all autopsied perinatal AIDS cases were born to drug injector mothers (Siminovich et al, unpublished data).
The current state of knowledge suggests that there will be no immediate resolution to the problem of drug injection itselfS2. Nevertheless, existing research provides a basis for establishing programmes to slow the spread of HIV infection among those who inject drugs. Entering and remaining in drug treatment programmes are factors associated with significant reductions in the rates of HIV infection among drug injectors. It is known that more drug users are entering rehabilitation programmes every year in Argentina (Chamo, unpublished data). However, care costs are higher for HIV infected than non-infected drug injectors's. Given the already existing need for resources for drug use treatment, these higher medical costs for HIV infected drug injectors will increase the demands on the limited resources of the health systems of both Argentina and Brazil.
Data presented here underscore the need to further intensify efforts to control the spread of AIDS in these two countries. The urgent need to confront the sexual transmission of HIV can only be matched by the necessity to address the control of HIV transmission by drug injection.
